<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68633">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01662440</url>
  </required_header>
  <id_info>
    <org_study_id>V49_23</org_study_id>
    <secondary_id>2011-005173-23</secondary_id>
    <nct_id>NCT01662440</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects</brief_title>
  <official_title>A Phase III, Multicenter, Observer-blind, Safety and Immunogenicity Study of Rabies Vaccine and Japanese Encephalitis Vaccine Administered Concomitantly and/or Separately According to 1 of 2 Different Preexposure Prophylaxis Schedules to Healthy Adult Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>Austria: Agency for Health and Food Safety</authority>
    <authority>Switzerland: Swissmedic</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Establish non-inferiority of the immune response and evaluate the safety and tolerability of
      Rabies and Japanese Encephalitis (JE) vaccines given concomitantly or alone and according to
      either of 2 schedules for preexposure prophylaxis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Non-inferiority of the immune response to Rabies vaccine (administered concomitantly with JE vaccine) accelerated versus conventional schedule.</measure>
    <time_frame>7 days after last active vaccine administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of subjects with Rabies Virus Neutralizing Antibodies (RVNA) titer ≥ 0.5 IU/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-inferiority of the immune response to JE vaccine (administered concomitantly with Rabies vaccine) accelerated versus conventional schedule.</measure>
    <time_frame>28 days after last active vaccine administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of subjects with Plaque Reduction Neutralization Test (PRNT50) titer ≥ 1:10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rabies Virus Neutralizing Antibody Geometric Mean Titer</measure>
    <time_frame>28 days after last active vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Non-inferiority of the immune response of Rabies + JE versus Rabies vaccine as per conventional vaccination schedule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plaque Reduction Neutralization Test(PRNT50)Geometric Mean Titer</measure>
    <time_frame>28 days after last active vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Non-inferiority of the immune response to JE + Rabies versus JE vaccine as per conventional vaccination schedule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with RVNA titer ≥0.5 IU/mL</measure>
    <time_frame>28 days after last active vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Non-inferiority of the immune response to Rabies + JE accelerated schedule versus Rabies vaccine as per conventional schedule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with PRNT50 ≥ 1:10</measure>
    <time_frame>7 days after last active vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Non-inferiority of the immune response to JE +Rabies accelerated schedule versus JE vaccine as per conventional schedule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with RVNA titer ≥ 0.5 IU/mL and RVNA Geometric Mean Titer</measure>
    <time_frame>Days 1, 8, 15, 36, 57, 91, 181 and 366</time_frame>
    <safety_issue>No</safety_issue>
    <description>Kinetics of antibody response for Rabies on Days 1, 8, 15, 36, 57, 91, 181 and 366.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with PRNT50 ≥ 1:10 and PRNT50 Geometric Mean Titer</measure>
    <time_frame>Days1, 15, 22, 36, 57, 91, 181 and Day 366</time_frame>
    <safety_issue>No</safety_issue>
    <description>Kinetics of antibody response for JE on Days1, 15, 22, 36, 57, 91, 181 and Day 366</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with solicited local reactions</measure>
    <time_frame>7 days following each vaccination.</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with solicited systemic and other reactions</measure>
    <time_frame>Day 1 (postvaccination) through Day 14 (inclusive) and Day 29 through Day 35 (inclusive).</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with all AEs (including SAEs and AEs leading to subject withdrawal)</measure>
    <time_frame>Day 1 (postvaccination) through Day 57 (upon completion of clinic visit).</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with all vaccine related SAEs</measure>
    <time_frame>Day 57 (post completion of clinic visit) through Day 366 (or study termination).</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with all concomitant medications</measure>
    <time_frame>Day 1 through Day 57</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">660</enrollment>
  <condition>Rabies</condition>
  <condition>Japanese Encephalitis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional (Rabies and JE Vaccines)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Accelerated (Rabies and JE Vaccines)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional (Rabies Vaccine alone)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional (JE Vaccine alone)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rabies</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Japanese Encephalitis</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females between 18 and 65 years of age (inclusive).

          2. Subjects who have given written consent.

          3. Individuals in good health as per investigator judgement.

        Exclusion Criteria:

          1. If female, pregnancy or unwillingness to practice acceptable contraception.

          2. If female, pregnant or breast-feeding female or any positive/indeterminate pregnancy
             test.

          3. Contraindication or precaution against Rabies and Japanese Encephalitis vaccination.

          4. Unable to comprehend and to follow all required study procedures for the whole period
             of the study.

          5. Participating in any other clinical trial 30 days prior to first study visit.

          6. History of previous rabies/rabies immunoglobulin and/or Japanese Encephalitis
             immunization.

          7. Receiving or planning to receive anti-malarial medications (e.g. Mefloquine) 14 days
             prior to Day 1 vaccination through Day 43.

          8. Received any other vaccines within 2 weeks prior to enrollment in this study or plan
             to receive any vaccine within 4 weeks from the study vaccines.

          9. Ever received blood, blood products and/or plasma derivatives or any parenteral
             immunoglobulin preparation in the past 12 weeks.

         10. Individuals who are part of study personnel or close family members conducting this
             study.

         11. Body temperature ≥38 degrees Celsius (≥ 100.4° F) within 3 days of intended study
             vaccination

         12. Plans to travel within the next year to areas where Rabies and/or Japanese
             Encephalitis vaccine may be considered or offered. This includes but is not limited
             to India, Asia, Pacific-Rim, African countries.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines and Diagnostics</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Specific Prophylaxis and Tropical Medicine Center for Pathophysiology, Infectious Diseases and Immunology Medical University of Vienna</name>
      <address>
        <city>Kinderspitalgasse 15</city>
        <state>Vienna</state>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bernhard Nocht Institute for Tropical Medicine</name>
      <address>
        <city>Bernhard-Nocht-Strasse 74</city>
        <state>Hamburg</state>
        <zip>D-20359</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Zurich</name>
      <address>
        <city>Rämistrasse 71</city>
        <state>Zürich</state>
        <zip>CH-8006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 4, 2013</lastchanged_date>
  <firstreceived_date>August 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rabies</keyword>
  <keyword>JE</keyword>
  <keyword>accelerated schedule</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Encephalitis, Japanese</mesh_term>
    <mesh_term>Rabies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
